Riobello Cristina, Vivanco Blanca, Reda Sara, López-Hernández Alejandro, García-Inclán Cristina, Potes-Ares Sira, Cabal Virginia N, López Fernando, Llorente José Luis, Hermsen Mario A
Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Hospital Universitario Central de Asturias, Oviedo, Spain.
Department of Pathology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Head Neck. 2018 Apr;40(4):818-827. doi: 10.1002/hed.25067. Epub 2018 Jan 22.
Sinonasal cancer carries a poor prognosis, especially in recurrent stages, and it is a disease with very limited treatment options.
The expression of programmed death ligand-1 (PD-L1) as a marker for immunotherapy was evaluated in 53 sinonasal squamous cell carcinoma (SCC) and 126 intestinal-type adenocarcinoma (ITAC) samples. Results were correlated to clinicopathological characteristics and follow-up data.
Membranous PD-L1 staining of tumor cells was observed in 34% (18/53) of the sinonasal SCC samples and in 17% (22/126) of the ITAC samples. The PD-L1 positivity on infiltrating immune cells occurred in 45% (24/53) of the sinonasal SCC samples and in 33% (41/126) of the ITAC samples. Expression of PD-L1 showed no correlation to clinicopathological parameters and was not an independent risk factor for survival.
The PD-L1 positivity does not seem to have prognostic value. However, a proportion of patients with sinonasal SCC and ITAC may benefit from therapy with immune checkpoint inhibitors that recently have been approved for clinical application in head and neck cancer.
鼻窦癌预后较差，尤其是在复发阶段，并且它是一种治疗选择非常有限的疾病。
在53例鼻窦鳞状细胞癌（SCC）和126例肠型腺癌（ITAC）样本中评估作为免疫治疗标志物的程序性死亡配体-1（PD-L1）的表达。结果与临床病理特征和随访数据相关。
在34%（18/53）的鼻窦SCC样本和17%（22/126）的ITAC样本中观察到肿瘤细胞膜性PD-L1染色。浸润免疫细胞上的PD-L1阳性出现在45%（24/53）的鼻窦SCC样本和33%（41/126）的ITAC样本中。PD-L1的表达与临床病理参数无关，且不是生存的独立危险因素。
PD-L1阳性似乎没有预后价值。然而，一部分鼻窦SCC和ITAC患者可能会从免疫检查点抑制剂治疗中获益，这些抑制剂最近已被批准用于头颈部癌的临床应用。
